Physician profile
Alok Kumar
NPI 1689672719
$2,487.49
in general payments reported to CMS, 2019-2025
22 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $244 · 2021: $367 · 2022: $159 · 2023: $153 · 2024: $156 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.23 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $448.08 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $391.69 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $318.30 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.49 | 2019-2025 | Jascayd |
| Insmed, INC. | $211.76 | 2020-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $196.28 | 2022-2025 | Opsumit, Uptravi |
| Jazz Pharmaceuticals INC. | $93.52 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $92.63 | 2022-2025 | Fanapt, Hetlioz |
| Genzyme Corporation | $88.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.88 | 2020-2021 | |
| Harmony Biosciences LLC | $59.61 | 2020-2022 | |
| Electromed, INC. | $49.53 | 2019-2021 | |
| Mylan Specialty L.P. | $38.22 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $32.72 | 2021 | |
| Amgen INC. | $25.71 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $23.35 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $21.01 | 2020 | |
| Horizon Therapeutics Plc | $19.86 | 2020 | |
| Lilly USA, LLC | $19.86 | 2025 | Zepbound |
| Allergan, INC. | $16.53 | 2020 | |
| Shionogi INC | $15.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.